Fact Meets Function

Exploring the therapeutic potential of β-nicotinamide mononucleotide (NMN) in regulating canine NT-proBNP levels.

This veterinary study demonstrates that oral NMN supplementation significantly reduces elevated NT-proBNP levels (a cardiac dysfunction biomarker) in dogs with preserved cardiac structure or mild-to-moderate elevation, likely through improved mitochondrial energy metabolism. NMN showed limited efficacy in severe heart disease and required combination with conventional therapy in complex cases. The findings suggest NMN has potential as an adjunctive cardioprotective agent in veterinary practice, though further controlled studies are needed to establish its clinical role.

Exploring the therapeutic potential of β-nicotinamide mononucleotide (NMN) in regulating canine NT-proBNP levels. Read Post »

The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation.

A phase I clinical trial found that oral NMN supplementation at 1,200 mg/day effectively increases NAD levels in both blood and brain tissue, with benefits requiring 2-4 weeks of sustained administration. The study showed once-daily dosing is sufficient and works equally well in healthy individuals and Parkinson’s patients. This provides clinical validation for NMN’s bioavailability and establishes evidence-based dosing protocols that practitioners can reference when prescribing Annular’s NMN product.

The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation. Read Post »

Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.

This animal study demonstrates that GHRP-6 (related to Annular’s Growth-1295) significantly improved heart function and reduced tissue damage after heart attack by enhancing mitochondrial metabolism and reducing inflammation. The research provides strong preclinical evidence for cardioprotective benefits of growth hormone-releasing peptides. This supports the therapeutic potential of Annular’s Growth-1295 for cardiovascular applications in clinical practice.

Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation. Read Post »

Atypical population pharmacokinetics of hydromethylthionine in patients with Alzheimer’s disease explains unexpected phase 3 trial results.

This study examined how methylene blue (hydromethylthionine) is processed in the body when given orally to Alzheimer’s patients versus healthy people. The researchers found that Alzheimer’s patients process the drug differently than expected, which helps explain why previous clinical trials had unexpected results. The drug targets tau protein clumps in the brain that contribute to Alzheimer’s disease and also has other brain benefits.

Atypical population pharmacokinetics of hydromethylthionine in patients with Alzheimer’s disease explains unexpected phase 3 trial results. Read Post »

Modulation of mitochondrial quality by exercise mimetics: A potential strategy for the prevention and treatment of Alzheimer’s disease.

This review examines how exercise mimetic compounds like SLU-PP-332 could help prevent and treat Alzheimer’s disease by improving cellular energy production. When brain cells can’t produce energy properly, it leads to the brain damage seen in Alzheimer’s. These compounds work by activating the same cellular pathways that exercise does, potentially offering benefits for patients who can’t exercise regularly. This suggests exercise mimetics could be a practical intervention for cognitive decline.

Modulation of mitochondrial quality by exercise mimetics: A potential strategy for the prevention and treatment of Alzheimer’s disease. Read Post »

Hyaluronic acid-ethylenediamine-cinnamic acid attenuates IBS-D via regulating 5-hydroxytryptamine signaling pathway, intestinal barrier and gut microbiota.

This animal model study investigated a hyaluronic acid-based compound (hyaluronic acid-ethylenediamine-cinnamic acid) in diarrhea-predominant irritable bowel syndrome (IBS-D), examining three potential mechanisms: serotonin (5-hydroxytryptamine) signaling, intestinal barrier function, and gut microbiota composition. The compound demonstrated effects on all three pathways in the animal model, suggesting a multi-target mechanism of action. This is **animal model-level evidence** and would require human clinical investigation before applicability to patient populations.

Hyaluronic acid-ethylenediamine-cinnamic acid attenuates IBS-D via regulating 5-hydroxytryptamine signaling pathway, intestinal barrier and gut microbiota. Read Post »

Development of Freeze-Dried Hyaluronic Acid Sheets for Healing Oral Mucositis: Influence of Hyaluronic Acid Molecular Weight and Nicotinamide Mononucleotide Loading on Healing Efficacy.

Researchers tested different formulations of hyaluronic acid sheets loaded with NMN to treat severe mouth sores that occur during cancer treatment. They found that 800 kDa hyaluronic acid sheets provided the best healing results in animal studies. The NMN-loaded sheets stayed in place well and released the compound steadily, showing promise as a safe treatment for painful mouth ulcers in cancer patients.

Development of Freeze-Dried Hyaluronic Acid Sheets for Healing Oral Mucositis: Influence of Hyaluronic Acid Molecular Weight and Nicotinamide Mononucleotide Loading on Healing Efficacy. Read Post »

Methylene Blue-Enriched Feed Mitigates Acute Nitrite Intoxication in Nile tilapia (Oreochromis niloticus).

This study tested whether methylene blue added to fish feed could protect tilapia from nitrite poisoning, which causes dangerous oxygen transport problems. Fish fed methylene blue for 5 days before nitrite exposure had no deaths and better blood oxygen levels compared to control fish that experienced deaths and organ damage. The methylene blue worked by preventing the conversion of healthy hemoglobin to dysfunctional methemoglobin. This suggests oral methylene blue could be an effective way to protect against oxygen transport disruption.

Methylene Blue-Enriched Feed Mitigates Acute Nitrite Intoxication in Nile tilapia (Oreochromis niloticus). Read Post »

Neutrophil-Driven Cascade-Targeted Nanocarriers Restore Mitochondrial Homeostasis to Ameliorate Renal Ischemia-Reperfusion Injury.

Researchers developed a targeted drug delivery system that uses NMN (a compound that boosts cellular energy) to treat kidney damage caused by reduced blood flow. In mouse studies, this system successfully delivered NMN directly to injured kidney cells, restored their energy production, and prevented both immediate kidney damage and long-term scarring. The treatment works by boosting NAD+ levels in kidney cells, which helps repair their cellular powerhouses (mitochondria).

Neutrophil-Driven Cascade-Targeted Nanocarriers Restore Mitochondrial Homeostasis to Ameliorate Renal Ischemia-Reperfusion Injury. Read Post »

β-Nicotinamide mononucleotide preserves muscle strength in septic male mice.

This study found that sepsis patients often develop persistent muscle weakness even after recovery, which is linked to damaged cellular powerhouses (mitochondria) in muscle tissue. Researchers discovered that NMN supplementation helped preserve muscle strength in septic mice by protecting these mitochondria. The treatment worked by supporting a key protein called SIRT3 that helps maintain healthy muscle cell energy production.

β-Nicotinamide mononucleotide preserves muscle strength in septic male mice. Read Post »

Alpha-ketoglutarate accelerates granulocyte-monocyte progenitor differentiation and atherosclerotic plaque inflammation via oxoglutarate receptor 1.

This animal study found that a high-fat diet increases alpha-ketoglutarate levels, which triggers a chain reaction that depletes NAD+ and NMN levels in immune cells. This depletion disrupts cellular energy production and increases inflammation, contributing to atherosclerosis (plaque buildup in arteries). The research suggests that maintaining adequate NAD+ and NMN levels may be important for cardiovascular health and controlling inflammation.

Alpha-ketoglutarate accelerates granulocyte-monocyte progenitor differentiation and atherosclerotic plaque inflammation via oxoglutarate receptor 1. Read Post »

Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis.

This animal study shows GHRP-6 (similar to Annular’s Growth-1295) significantly reduced lung injury and prevented progression to pulmonary fibrosis in mice. The peptide reduced inflammation, improved lung function, and preserved tissue integrity in both acute and chronic scenarios. This is the first study demonstrating lung protective effects for this class of peptides, potentially expanding therapeutic applications beyond traditional growth hormone benefits.

Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis. Read Post »

Scroll to Top